{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:24:24Z","timestamp":1778498664821,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013428","name":"Stichting Spieren voor Spieren","doi-asserted-by":"publisher","award":["SvS2019001"],"award-info":[{"award-number":["SvS2019001"]}],"id":[{"id":"10.13039\/501100013428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Progressive decreases in joint range of motion (ROM) is a well-recognized complication in the natural history of spinal muscular atrophy (SMA). How joint ROM evolves in children with SMA receiving disease-modifying treatment (DMT) needs to be documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To examine the longitudinal course of joint range of motion in young children with SMA receiving disease-modifying therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We included children with SMA (with 2 or 3\n                      <jats:italic>SMN<\/jats:italic>\n                      2 copies) who started treatment within the first 18 months of life in a prospective national tertiary cohort study. Our examination consisted of joint range of motion of the knee, elbow and wrist; the longitudinal course was studied using linear mixed-effects models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We analysed 165 visits of 39 children (median age 22 months (interquartile range [6\u201345])) with treated SMA over a 3-year follow-up period. The median age at start of treatment was 2 months [0\u20138]. We found an average yearly decline in knee extension mobility of 3\u00b0. The overall course of range of motion for elbow and wrist remained stable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The course of joint mobility in children with SMA, who started treatment with DMT in the first 18 months of life, is characterised by a decline in knee extension and a stable range of motion of wrist and elbow joints. We stress the importance of monitoring knee extension range of motion at least every 6 months and adopting a proactive approach to maintain full knee extension for optimal lifelong mobility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04109-0","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:20:35Z","timestamp":1763547635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Course of joint range of motion in children with spinal muscular atrophy receiving disease-modifying treatment"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4381-6176","authenticated-orcid":false,"given":"I. L. B.","family":"Oude Lansink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. W.","family":"Gorter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. L.","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. R.","family":"vd Woude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. J.","family":"Scheiberlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. P. A.","family":"van Eijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"4109_CR1","doi-asserted-by":"crossref","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell [Internet]. 1995;80(1):155\u201365. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7813012","DOI":"10.1016\/0092-8674(95)90460-3"},{"key":"4109_CR2","doi-asserted-by":"crossref","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci [Internet]. 1997;146(1):67\u201372. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9077498","DOI":"10.1016\/S0022-510X(96)00284-5"},{"key":"4109_CR3","doi-asserted-by":"crossref","unstructured":"Wijngaarde CA, Stam M, Otto LAM, van Eijk RPA, Cuppen I, Veldhoen ES, et al. Population-based analysis of survival in spinal muscular atrophy. Neurology [Internet]. 2020;94(15):e1634\u201344. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32217777","DOI":"10.1212\/WNL.0000000000009248"},{"key":"4109_CR4","doi-asserted-by":"crossref","unstructured":"Wijngaarde CA, Veldhoen ES, van Eijk RPA, Stam M, Otto LAM, Asselman FL, et al. Natural history of lung function in spinal muscular atrophy. Orphanet J Rare Dis [Internet]. 2020;15(1):88. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32276635","DOI":"10.1186\/s13023-020-01367-y"},{"key":"4109_CR5","doi-asserted-by":"crossref","unstructured":"Wadman RI, Wijngaarde CA, Stam M, Bartels B, Otto LAM, Lemmink HH, et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4. Eur J Neurol [Internet]. 2018;25(3):512\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29194869","DOI":"10.1111\/ene.13534"},{"key":"4109_CR6","unstructured":"Pechmann A, Behrens M, D\u00f6rnbrack K, Tassoni A, Stein S, Vogt S, et al. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy. Brain [Internet]. 2023;146(2):668\u201377. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35857854"},{"key":"4109_CR7","doi-asserted-by":"crossref","unstructured":"Erdos J, Wild C. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data. Eur J Paediatr Neurol [Internet]. 2022;39:1\u201310. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35533607","DOI":"10.1016\/j.ejpn.2022.04.006"},{"key":"4109_CR8","doi-asserted-by":"crossref","unstructured":"Giess D, Erdos J, Wild C. An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies. Eur J Paediatr Neurol [Internet]. 2024;51:84\u201392. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38905882","DOI":"10.1016\/j.ejpn.2024.06.004"},{"key":"4109_CR9","doi-asserted-by":"crossref","unstructured":"Wei\u00df C, Ziegler A, Becker LL, Johannsen J, Brennenstuhl H, Schreiber G, et al. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health [Internet]. 2022;6(1):17\u201327. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34756190","DOI":"10.1016\/S2352-4642(21)00287-X"},{"key":"4109_CR10","doi-asserted-by":"crossref","unstructured":"Wijngaarde CA, Brink RC, de Kort FAS, Stam M, Otto LAM, Asselman FL, et al. Natural course of scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy. Neurology [Internet]. 2019;93(2):e149\u201358. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31164393","DOI":"10.1212\/WNL.0000000000007742"},{"key":"4109_CR11","doi-asserted-by":"crossref","unstructured":"Carter GT, Abresch RT, Fowler WM, Johnson ER, Kilmer DD, McDonald CM. Profiles of neuromuscular diseases. Spinal muscular atrophy. Am J Phys Med Rehabil [Internet]. 1995;74(5 Suppl):S150-9. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7576422","DOI":"10.1097\/00002060-199509001-00009"},{"key":"4109_CR12","doi-asserted-by":"crossref","unstructured":"Fujak A, Kopschina C, Gras F, Forst R, Forst J. Contractures of the lower extremities in spinal muscular atrophy type II. Descriptive clinical study with retrospective data collection. Ortop Traumatol Rehabil [Internet]. 2011;13(1):27\u201336. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21393646","DOI":"10.5604\/15093492.933792"},{"key":"4109_CR13","doi-asserted-by":"crossref","unstructured":"Willig TN, Bach JR, Rouffet MJ, Krivickas LS, Maquet C. Correlation of flexion contractures with upper extremity function and pain for spinal muscular atrophy and congenital myopathy patients. Am J Phys Med Rehabil [Internet]. 1995;74(1):33\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7873112","DOI":"10.1097\/00002060-199501000-00006"},{"key":"4109_CR14","doi-asserted-by":"crossref","unstructured":"Wang HY, Ju YH, Chen SM, Lo SK, Jong YJ. Joint range of motion limitations in children and young adults with spinal muscular atrophy. Arch Phys Med Rehabil [Internet]. 2004;85(10):1689\u201393. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15468032","DOI":"10.1016\/j.apmr.2004.01.043"},{"key":"4109_CR15","doi-asserted-by":"crossref","unstructured":"Salazar R, Montes J, Dunaway Young S, McDermott MP, Martens W, Pasternak A, et al. Quantitative evaluation of lower extremity joint contractures in spinal muscular atrophy: implications for motor function. Pediatr Phys Ther [Internet]. 2018;30(3):209\u201315. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29924070","DOI":"10.1097\/PEP.0000000000000530"},{"key":"4109_CR16","unstructured":"Johnson ER, Fowler WM, Lieberman JS. Contractures in neuromuscular disease. Arch Phys Med Rehabil [Internet]. 1992;73(9):807\u201310. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1514888"},{"key":"4109_CR17","doi-asserted-by":"crossref","unstructured":"Iannaccone ST, Browne RH, Samaha FJ, Buncher CR. Prospective study of spinal muscular atrophy before age 6 years. DCN\/SMA Group. Pediatr Neurol [Internet]. 1993;9(3):187\u201393. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8352849","DOI":"10.1016\/0887-8994(93)90082-N"},{"key":"4109_CR18","unstructured":"Fujak A, Kopschina C, Gras F, Forst R, Forst J. Contractures of the upper extremities in spinal muscular atrophy type II. Descriptive clinical study with retrospective data collection. Ortop Traumatol Rehabil [Internet]. 2010;12(5):410\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21057148"},{"key":"4109_CR19","doi-asserted-by":"crossref","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, et al. The Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol [Internet]. 2008;61(4):344\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18313558","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"4109_CR20","unstructured":"Dutch reimbursement law. https:\/\/wetten.overheid.nl\/BWBR0018715 (Accessed at 20-08-2025)."},{"key":"4109_CR21","unstructured":"Becher J. Handleiding Standaard Lichamelijk Onderzoek. Bohn Stafleu van Loghum; 2019."},{"key":"4109_CR22","doi-asserted-by":"crossref","unstructured":"Deymeer F, Serdaroglu P, Parman Y, Poda M. Natural history of SMA IIIb: muscle strength decreases in a predictable sequence and magnitude. Neurology [Internet]. 2008;71(9):644\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18725590","DOI":"10.1212\/01.wnl.0000324623.89105.c4"},{"key":"#cr-split#-4109_CR23.1","doi-asserted-by":"crossref","unstructured":"Piepers S, van der Pol WL, Brugman F, Wokke JHJ, van den Berg LH. Natural history of SMA IIIb: muscle strength decreases in a predictable sequence and magnitude. Neurology [Internet]. 2009;72(23):2057-8","DOI":"10.1212\/01.wnl.0000349698.94744.1e"},{"key":"#cr-split#-4109_CR23.2","unstructured":"author reply 2058. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19506238"},{"key":"4109_CR24","doi-asserted-by":"crossref","unstructured":"Piepers S, van den Berg LH, Brugman F, Scheffer H, Ruiterkamp-Versteeg M, van Engelen BG, et al. A natural history study of late onset spinal muscular atrophy types 3b and 4. J Neurol [Internet]. 2008;255(9):1400\u20134. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18575920","DOI":"10.1007\/s00415-008-0929-0"},{"key":"4109_CR25","doi-asserted-by":"crossref","unstructured":"Shimizu-Motohashi Y, Chiba E, Mizuno K, Yajima H, Ishiyama A, Takeshita E, et al. Muscle impairment in MRI affect variability in treatment response to nusinersen in patients with spinal muscular atrophy type 2 and 3: A retrospective cohort study. Brain Dev [Internet]. 2023;45(3):161\u201370. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36460551","DOI":"10.1016\/j.braindev.2022.11.002"},{"key":"4109_CR26","unstructured":"R Core Team. (2023). _R: A Language and Environment for Statistical Computing_. R Foundation for Statistical Computing, Vienna, Austria. Available from: https:\/\/www.R-project.org\/"},{"key":"4109_CR27","doi-asserted-by":"crossref","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S. Fitting linear Mixed-Effects models using lme4. J Stat Softw. 2015;67(1).","DOI":"10.18637\/jss.v067.i01"},{"key":"4109_CR28","unstructured":"Wickham H, Wickham H. ggplot2: Elegant Graphics for Data Analysis Second Edition [Internet]. 2016. Available from: http:\/\/www.springer.com\/series\/6991"},{"key":"4109_CR29","doi-asserted-by":"crossref","unstructured":"Harding ER, Kanner CH, Pasternak A, Glanzman AM, Dunaway Young S, Rao AK, et al. Beyond contractures in spinal muscular atrophy: identifying lower-limb joint hypermobility. J Clin Med [Internet]. 2024;13(9). Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38731167","DOI":"10.3390\/jcm13092634"},{"key":"4109_CR30","doi-asserted-by":"crossref","unstructured":"Matesanz SE, Curry C, Gross B, Rubin AI, Linn R, Yum SW, et al. Clinical course in a patient with spinal muscular atrophy type 0 treated with nusinersen and onasemnogene abeparvovec. J Child Neurol [Internet]. 2020;35(11):717\u201323. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32515646","DOI":"10.1177\/0883073820928784"},{"key":"4109_CR31","doi-asserted-by":"crossref","unstructured":"Bieniaszewska A, Sobieska M, Gajewska E. Prospective analysis of functional and structural changes in patients with spinal muscular atrophy-a pilot study. Biomedicines [Internet]. 2022;10(12). Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36551943","DOI":"10.3390\/biomedicines10123187"},{"key":"4109_CR32","doi-asserted-by":"crossref","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet [Internet]. 2016;388(10063):3017\u201326. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27939059","DOI":"10.1016\/S0140-6736(16)31408-8"},{"key":"4109_CR33","doi-asserted-by":"crossref","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med [Internet]. 2018;378(7):625\u201335. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29443664","DOI":"10.1056\/NEJMoa1710504"},{"key":"4109_CR34","doi-asserted-by":"crossref","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med [Internet]. 2017;377(18):1723\u201332. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29091570","DOI":"10.1056\/NEJMoa1702752"},{"key":"4109_CR35","doi-asserted-by":"crossref","unstructured":"McKay MJ, Baldwin JN, Ferreira P, Simic M, Vanicek N, Burns J, et al. Normative reference values for strength and flexibility of 1,000 children and adults. Neurology [Internet]. 2017;88(1):36\u201343. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27881628","DOI":"10.1212\/WNL.0000000000003466"},{"key":"4109_CR36","doi-asserted-by":"crossref","unstructured":"Rose KJ, Burns J, Wheeler DM, North KN. Interventions for increasing ankle range of motion in patients with neuromuscular disease. Cochrane Database Syst Rev [Internet]. 2010;(2):CD006973. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20166090","DOI":"10.1002\/14651858.CD006973.pub2"},{"key":"4109_CR37","doi-asserted-by":"crossref","unstructured":"Sackley C, Disler PB, Turner-Stokes L, Wade DT, Brittle N, Hoppitt T. Rehabilitation interventions for foot drop in neuromuscular disease. Cochrane Database Syst Rev [Internet]. 2009;(3):CD003908. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19588347","DOI":"10.1002\/14651858.CD003908.pub3"},{"key":"4109_CR38","doi-asserted-by":"crossref","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord [Internet]. 2018;28(2):103\u201315. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29290580","DOI":"10.1016\/j.nmd.2017.11.004"},{"key":"4109_CR39","doi-asserted-by":"crossref","unstructured":"Skalsky AJ, McDonald CM. Prevention and management of limb contractures in neuromuscular diseases. Phys Med Rehabil Clin N Am [Internet]. 2012;23(3):675\u201387. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22938881","DOI":"10.1016\/j.pmr.2012.06.009"},{"key":"4109_CR40","doi-asserted-by":"crossref","unstructured":"Glanzman AM, Swenson AE, Kim H. Intrarater range of motion reliability in cerebral palsy: a comparison of assessment methods. Pediatr Phys Ther [Internet]. 2008;20(4):369\u201372. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19011528","DOI":"10.1097\/PEP.0b013e31818b7994"},{"key":"4109_CR41","doi-asserted-by":"crossref","unstructured":"McWhirk LB, Glanzman AM. Within-session inter-rater realiability of goniometric measures in patients with spastic cerebral palsy. Pediatr Phys Ther [Internet]. 2006;18(4):262\u20135. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17108799","DOI":"10.1097\/01.pep.0000234960.88761.97"},{"key":"4109_CR42","doi-asserted-by":"crossref","unstructured":"Pandya S, Florence JM, King WM, Robison JD, Oxman M, Province MA. Reliability of goniometric measurements in patients with duchenne muscular dystrophy. Phys Ther [Internet]. 1985;65(9):1339\u201342. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/4034668","DOI":"10.1093\/ptj\/65.9.1339"},{"key":"4109_CR43","doi-asserted-by":"crossref","unstructured":"van Rijn SF, Zwerus EL, Koenraadt KL, Jacobs WC, van den Bekerom MP, Eygendaal D. The reliability and validity of goniometric elbow measurements in adults: A systematic review of the literature. Shoulder Elbow [Internet]. 2018;10(4):274\u201384. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30214494","DOI":"10.1177\/1758573218774326"},{"key":"4109_CR44","doi-asserted-by":"publisher","first-page":"S198","DOI":"10.1016\/j.jval.2021.04.991","volume":"24","author":"N Johnson","year":"2021","unstructured":"Johnson N, Paradis AD, Dave V, Macahilig C, Johnson C, Stephens JM, et al. PRO6 clinical and ambulatory characteristics in adult patients with spinal muscular atrophy: A natural history Multi-Country chart review study. Value Health. 2021;24:S198.","journal-title":"Value Health"},{"key":"4109_CR45","doi-asserted-by":"crossref","unstructured":"Otto LAM, van der Pol WL, Schlaffke L, Wijngaarde CA, Stam M, Wadman RI, et al. Quantitative MRI of skeletal muscle in a cross-sectional cohort of patients with spinal muscular atrophy types 2 and 3. NMR Biomed [Internet]. 2020;33(10):e4357. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32681555","DOI":"10.1002\/nbm.4357"},{"key":"4109_CR46","doi-asserted-by":"crossref","unstructured":"Hooijmans MT, Habets LE, van den Berg-Faay SAM, Froeling M, Asselman FL, Strijkers GJ, et al. Multi-parametric quantitative magnetic resonance imaging of the upper arm muscles of patients with spinal muscular atrophy. NMR Biomed [Internet]. 2022;35(7):e4696. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35052014","DOI":"10.1002\/nbm.4696"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04109-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04109-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04109-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:20:41Z","timestamp":1763547641000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-04109-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4109"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04109-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Medical Ethics Committee of the University Medical Center Utrecht, The Netherlands classified this study as exempt from the Medical Research Involving Human Subjects Act (20\u2013791).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants gave written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests. IOL: research grant from Stichting Spieren voor Spieren (SvS2019001). JWG: no conflicts of interest. WLP: Research grants from Prinses Beatrix Spierfonds and Stichting Spieren voor Spieren, both non-profit foundations. His employer receives fees for SMA-related consultancy activities. DW: his employer receives fees for SMA-related consultancy activities. PS: no conflicts of interest. RE: no conflicts of interest. BB: Research grants from Prinses Beatrix Spierfonds, Stichting Spieren voor Spieren and Piet Poortmanfonds, all non-profit foundations. His employer receives fees for SMA-related consultancy activities. AB: no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"592"}}